Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Combined hormonal contraceptives and migraine: An update on the evidence

Anne H. Calhoun, MD, FAHS and Pelin Batur, MD, FACP, NCMP
Cleveland Clinic Journal of Medicine August 2017, 84 (8) 631-638; DOI: https://doi.org/10.3949/ccjm.84a.16033
Anne H. Calhoun
Partner and Co-Founder, Carolina Headache Institute, Chapel Hill, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pelin Batur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Serum estradiol levels in the natural menstrual cycle (top) and with high-dose cyclic and low-dose continuous combined oral contraceptives (bottom).

Tables

  • Figures
    • View popup
    TABLE 1

    Combined hormonal contraceptives that can help prevent menstrual-related migraine

    Brand nameGeneric alternativesDoseClinical pearls
    Continuous formulations
    LybrelaAshlyna 28
    Amethyst 28a
    Ethinyl estradiol 20 µg and levonorgestrel 0.09 mg once daily for 365 days/yearCan substitute any generic 20-µg ethinyl estradiol pill and continue without placebo pills
    NuvaRingNone (though many insurance plans cover it)Vaginal ring
    Delivers ethinyl estradiol 15 µg and etonogestrel 0.12 mg daily
    Can be inserted once every 4 weeks to be used in a continuous fashion
    Women who are sensitive to the drop in estrogen level in the last week may need to replace the ring every 3 weeks
    Extended formulations
    LoSeasoniqueAmethia Lo
    Camrese Lo
    Ethinyl estradiol 20 µg and levonorgestrel 0.1 mg for 84 days, then ethinyl estradiol 10 µg for 7 daysIf a 30-µg ethinyl estradiol pill is used, will need to take it continuously to avoid triggering migraine
    Monthly formulations
    Lo Loestrin 1/10NoneEthinyl estradiol 10 µg and norethindrone 1 mg for 24 days, then ethinyl estradiol 10 µg for 2 days, then placebo for 2 daysUltra-low doses may be associated with increased breakthrough bleeding; the bleeding can improve over time
    NataziaNoneEstradiol valerate doses gradually decrease from 3 to 2 to 1 mg; dienogest dose increases from 2 to 3 mgThis pill pack has a different missed-pill algorithm; refer to package insert for specific instructions
    • ↵a Brand recently discontinued in the United States.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 84 (8)
Cleveland Clinic Journal of Medicine
Vol. 84, Issue 8
1 Aug 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combined hormonal contraceptives and migraine: An update on the evidence
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Combined hormonal contraceptives and migraine: An update on the evidence
Anne H. Calhoun, Pelin Batur
Cleveland Clinic Journal of Medicine Aug 2017, 84 (8) 631-638; DOI: 10.3949/ccjm.84a.16033

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combined hormonal contraceptives and migraine: An update on the evidence
Anne H. Calhoun, Pelin Batur
Cleveland Clinic Journal of Medicine Aug 2017, 84 (8) 631-638; DOI: 10.3949/ccjm.84a.16033
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • WHAT THE GUIDELINES SAY
    • EARLY ORAL CONTRACEPTIVES WERE ALL HIGH-DOSE
    • DIAGNOSTIC CRITERIA FOR MIGRAINE
    • MIGRAINE IS COMMON AND UNDERRECOGNIZED
    • HOW ESTROGEN AFFECTS MIGRAINE
    • STROKE RISK: ESTROGEN DOSE MATTERS
    • STROKE RISK INCREASES WITH FREQUENCY OF MIGRAINE AURA
    • CHOOSING THE OPTIMAL CONTRACEPTIVE FORMULATION
    • ADVISING PATIENTS ON RISKS VS BENEFITS
    • WHAT WOULD WE DO?
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Paternalism in practice: How we create obstacles for sexual, reproductive, and menopausal healthcare despite our best intentions
  • Migraine and risk of stroke
  • Migraine: navigating the hormonal minefield
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Drug Therapy
  • Neurology
  • Women's Health

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire